On Monday, Elevation Oncology Inc (NASDAQ: ELEV) opened higher 3.09% from the last session, before settling in for the closing price of $0.65. Price fluctuations for ELEV have ranged from $0.36 to $5.83 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 36.19% at the time writing. With a float of $50.00 million, this company’s outstanding shares have now reached $59.12 million.
Considering the fact that the conglomerate employs 29 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 50.0%, operating margin of -72425.86%, and the pretax margin is -72250.0%.
Elevation Oncology Inc (ELEV) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Elevation Oncology Inc is 15.43%, while institutional ownership is 93.91%.
Elevation Oncology Inc (ELEV) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.19 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.24) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 36.19% per share during the next fiscal year.
Elevation Oncology Inc (NASDAQ: ELEV) Trading Performance Indicators
Check out the current performance indicators for Elevation Oncology Inc (ELEV). In the past quarter, the stock posted a quick ratio of 17.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.81, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.91 in one year’s time.
Technical Analysis of Elevation Oncology Inc (ELEV)
Compared to the last year’s volume of 1.57 million, its volume of 0.95 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 71.71%. Additionally, its Average True Range was 0.06.
During the past 100 days, Elevation Oncology Inc’s (ELEV) raw stochastic average was set at 6.12%, which indicates a significant decrease from 74.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.95% in the past 14 days, which was lower than the 174.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5844, while its 200-day Moving Average is $2.5477. Nevertheless, the first resistance level for the watch stands at $0.7187 in the near term. At $0.7675, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8143. If the price goes on to break the first support level at $0.6231, it is likely to go to the next support level at $0.5763. Now, if the price goes above the second support level, the third support stands at $0.5275.
Elevation Oncology Inc (NASDAQ: ELEV) Key Stats
There are currently 59,119K shares outstanding in the company with a market cap of 44.60 million. Presently, the company’s annual sales total 0 K according to its annual income of -45,700 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -10,460 K.
